Literature DB >> 11551598

Insulins today and beyond.

D R Owens1, B Zinman, G B Bolli.   

Abstract

The advent of insulin almost 80 years ago revolutionised treatment of diabetes and must be one of the most outstanding achievements of twentieth century medicine. Since then, there has been an ever-increasing awareness and acceptance of the need to achieve and sustain near-normoglycaemia to delay onset and retard progression of diabetic angiopathy. Physiological insulin replacement is therefore central to management of patients with diabetes who are unable to make [corrected] insulin. Insulin formulations, treatment strategies, and methods and routes of delivery have changed much, with more and more options for monitoring the effect on blood glucose concentrations. Patients with type 1 and type 2 diabetes need insulin much more aggressively than previously. Parallel developments in glucose-sensing technologies are welcomed as an integral part of safe and optimum implementation of insulin replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551598     DOI: 10.1016/S0140-6736(01)05842-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  60 in total

1.  Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues.

Authors:  Fariba Shojaee-Moradie; Michelle P Y Chan; Micayla A Telfer; Dietrich Brandenburg; Erik Sundermann; Heike Eckey; Jens Kleinjung; Achim Schüttler; Richard H Jones
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

Review 2.  The utility and efficacy of the new insulins in the management of diabetes and pregnancy.

Authors:  David Simmons
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

3.  Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia.

Authors:  Jicheng Yu; Yuqi Zhang; Wujin Sun; Anna R Kahkoska; Jinqiang Wang; John B Buse; Zhen Gu
Journal:  Small       Date:  2017-03-20       Impact factor: 13.281

Review 4.  Glucose-Responsive Microneedle Patches for Diabetes Treatment.

Authors:  Guojun Chen; Jicheng Yu; Zhen Gu
Journal:  J Diabetes Sci Technol       Date:  2018-05-31

5.  Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.

Authors:  A Siebenhofer; J Plank; A Berghold; K Horvath; P T Sawicki; P Beck; T R Pieber
Journal:  Diabetologia       Date:  2004-11-25       Impact factor: 10.122

6.  Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery.

Authors:  Yanqi Ye; Jicheng Yu; Chao Wang; Nhu-Y Nguyen; Glenn M Walker; John B Buse; Zhen Gu
Journal:  Adv Mater       Date:  2016-03-01       Impact factor: 30.849

Review 7.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

8.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

9.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

10.  A test of the reliability and validity of a diabetes specific quality of life scale in a Nigerian hospital.

Authors:  B A Kolawole; O Abodunde; R T Ikem; A K Fabiyi
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.